Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > COMMENTARY
COMMENTARY
-
Further Provisions Required – One Year since the Great East Japan Earthquake
March 12, 2012
-
Major US, European Drug Makers Report Growth in 2011 as Patent Cliff Approaches
March 5, 2012
-
Will Wholesalers Be Able to Succeed at Reform This Time?
February 20, 2012
-
Industry Should Prepare Arguments in Advance to Ward Off Possibility of 3 Consecutive NHI Price Revisions
January 23, 2012
-
Will New Drug Makers Dominate Domestic Biosimilars Market?
December 26, 2011
-
Pressure Mounting for Additional NHI Price Cut for Long-listed Drugs
December 12, 2011
-
“Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?
November 28, 2011
-
Perpetuation of Premium for New Drug Development Faces Hurdles
November 14, 2011
-
Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
November 14, 2011
-
Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
-
Pinning Hope on Academia in Seeking a Radical Cure for AD
October 10, 2011
-
New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
October 3, 2011
-
Discussions on Amendment of PAL Now in Final Stages
October 3, 2011
-
Korosho Revises GL for Drafting, Distributing Drug Safety Information
September 5, 2011
-
Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
-
Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
-
Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
-
Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
July 18, 2011
-
Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
-
Era of Competition Dawns in Market for AD Treatments
June 27, 2011
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…